1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Gloo Holdings reported first quarter 2026 revenue of $41.5 million, up 238% from the prior-year period, and a net loss of $17.1 million, down from $27.0 million a year earlier. The company raised its fiscal 2026 revenue guidance to $195.0 million and guided second quarter revenue to $44.0 million and Adjusted EBITDA to negative $8.5 million. Shareholders get a clearer view of growth and a narrowing loss, though the company still reports a net loss and has not reached Adjusted EBITDA profitability.
Q1 2026 total revenue was $41.5 million, versus $12.3 million in the prior-year period, and above the $36.0 million consensus cited in the release.
Net loss narrowed to $17.1 million from $27.0 million; Adjusted EBITDA was negative $11.5 million, compared with negative $18.6 million in Q4 2025.
Fiscal 2026 revenue guidance raised to $195.0 million; Q2 2026 revenue expected at $44.0 million and Adjusted EBITDA at negative $8.5 million.
Gloo agreed to acquire the remaining 20% stake in Midwestern, which would remove a $12.1 million call option liability from its balance sheet.
Mama's Creations reported first-quarter fiscal 2027 results for the period ended April 30, 2026. Revenue rose 50% to $52.8 million and net income rose 66% to $2.1 million, or $0.05 per diluted share, but gross margin fell to 23.6% from 26.1%, which the company attributed to short-term start-up inefficiencies tied to new product launches. Cash and cash equivalents reached $24.4 million, and total debt was $5.1 million.
Revenue of $52.8 million versus $35.3 million a year earlier, up 49.7%
Net income of $2.1 million, or $0.05 per diluted share, versus $1.2 million, or $0.03, a year earlier
Gross margin of 23.6% versus 26.1%; management cited labor and raw material inefficiencies from new packaging and product start-ups
Cash of $24.4 million as of April 30, 2026, up from $20.0 million on January 31, 2026; total debt $5.1 million
Oil-Dri reported third-quarter fiscal 2026 results for the quarter ended April 30, 2026, with net sales of $126.3 million, up 9%, and net income of $14.5 million, up 25%. Its board also raised the quarterly dividend by about 10% and authorized repurchases of up to 500,000 more Common shares, though nine-month income from operations fell 5%.
Q3 net sales $126.3 million, up 9%; diluted EPS (Common) $1.00 versus $0.80 a year earlier.
Gross margin fell to 26.7% from 28.6%, partly offset by SG&A expenses down $2.5 million, or 13%.
Board declared quarterly dividend of $0.225 per Common share, payable August 21, 2026 to holders of record August 7, 2026.
Board authorized repurchase of up to 500,000 Common shares, in addition to 172,261 Common and 208,197 Class B shares available as of April 30, 2026.
Vor Bio announced that China's National Medicinal Products Administration granted conditional approval of telitacicept for adult IgA nephropathy and approval for adult Sjögren's disease, both in China, where partner RemeGen holds development and commercialization rights. Vor Bio holds exclusive rights outside Greater China, so the filing signals progress on the drug's global program but no direct financial figures are disclosed.
NMPA conditionally approved telitacicept for adult IgA nephropathy in China, per Exhibit 99.1.
NMPA approved telitacicept for adult Sjögren's disease in China, per Exhibit 99.2.
In the Phase 3 TELIGAN trial, telitacicept 240 mg produced a 55% placebo-adjusted reduction in UPCR at Week 39.
RemeGen runs development and commercialization in China; Vor Bio holds rights outside Greater China.
U.S. Global Investors restated per-share results for the three and nine months ended March 31, 2026, after a spreadsheet omission understated weighted-average shares. The error changed only share counts and EPS; net income, revenue and operating income were not affected. Restated Q3 net income of $2.7 million compares with a net loss a year earlier, so shareholders see lower per-share figures but unchanged underlying profit.
Restated Q3 basic and diluted EPS is $0.21, down from $0.23 as reported; nine-month EPS is $0.26, down from $0.27.
Weighted-average shares for the quarter were understated by 702,484 shares; the company said net income, revenue and cash were not affected.
Q3 operating revenues were $2.8 million, up 31% from the same quarter of fiscal 2025 and up 10% from the prior quarter.
Q3 net income was $2.7 million, compared with a net loss of $382 thousand in the same quarter a year earlier.
Motorcar Parts of America reported fiscal 2026 fourth-quarter net sales up 9.9% to $212.3 million and net income of $9.7 million, or $0.42 per diluted share, versus a net loss of $722,000 a year earlier. For fiscal 2027 the company expects net sales of $780 million to $800 million, operating income of $86 million to $91 million, and EBITDA of $95 million to $100 million, which would be a meaningful increase in profit against fiscal 2026 operating income of $65.8 million.
Q4 fiscal 2026 net sales rose $19.2 million, or 9.9%, to $212.3 million, including $19.9 million of core revenue tied to inventory realignment at customer distribution centers.
Full-year fiscal 2026 net income was $12.4 million, or $0.62 per diluted share, versus a net loss of $19.5 million a year earlier; operating income was $65.8 million versus $39.9 million.
Fiscal 2027 guidance: net sales of $780 million to $800 million, operating income of $86 million to $91 million, and EBITDA of $95 million to $100 million.
The company repurchased 955,608 shares for $11.4 million in fiscal 2026 and had $22.1 million remaining under its current buyback authorization as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.